MarketInOut Stock Screener Log In | Sign Up

Medicenna Therapeutics Corp

TSX • Healthcare • Biotechnology • Quote as of 10/27/2026 15:57
Medicenna Therapeutics Corp stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeTSX
Market Capitalization39.23 mln
Float62.41 mln
Earnings Date11/12/2026

Piotroski F-Score

1 / 9
Very weak

Relative Strength

40 / 100
Slightly lagging

Debt / Equity

0.06
Debt-free

ROE

-263
Deeply negative

ROA

-132
Deeply negative

Business Description

Medicenna Therapeutics Corp. is a Toronto-based medical company focused on developing new treatments for cancer, inflammation, and immune-related diseases. Its lead drug candidate targets recurrent glioblastoma, an aggressive form of brain cancer, while its broader pipeline includes therapies designed to strengthen the immune system's ability to fight tumors and others aimed at calming harmful immune responses in conditions like multiple sclerosis. The company's approach centers on engineering enhanced versions of naturally occurring immune proteins to improve their precision and effectiveness.

Key Fundamentals

EPS-0.22
ROE-263
ROIC-478
ROA-132
EBITDA, mln-19.78
EV / EBITDA-1.15
EV / EBIT-1.15

Quote Details

Last 0.43
Change 0.005 (1.18%)
Open 0.42
Volume 16,006
Turnover 6,882.58
Average Volume 51,421

Financial Ratios

Leverage Ratio4.93
Current Ratio1.25
Price / Book21.94
Price / Tangible Book19.75
Debt / Equity0.06

Financial Strength

Piotroski F-Score 1 / 9
Short Ratio4.42
Short % of Float0.51

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 10.26% 98 / 100   
1 Month 6.17% 88 / 100   
2 Months 22.86% 92 / 100   
6 Months -33.85% 5 / 100   
1 Year -59.43% 2 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog